Pharmacological Inhibition of the AQP4 Water Channel Activity Causes an Aggravation of Alpha-Synuclein Pathology in the Substantia Nigra in a Rat Model of Parkinson’s Disease

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

The misfolding of the protein α-synuclein, which leads to the formation of neurototoxic oligomers and aggregates, is one of the main causes of loss of dopaminergic (DA) neurons within the substantia nigra pars compacta (SNpc) in Parkinson’s disease (PD). We previously found that pharmacological inhibition of the water channel aquaporin-4 (AQP4), participating in the mechanisms of brain clearance of amyloidogenic proteins, caused the aggravation of neurodegeneration in the nigrostriatal system and the development of motor disturbances in a lactacystin model of PD. It was hypothesized that the progression of neurodegeneration can be a result of the excessive accumulation of pathologic forms of α-synuclein due to the AQP4 inhibition. The aim of this study is to determine whether pharmacological inhibition of AQP4 activity in a rat model of preclinical PD leads to an aggravation in α-synuclein pathology. The experiments were performed on male Wistar rats. AQP4 activity was suppressed using the intracerebroventricular injection of inhibitor TGN-020. To reproduce the model of the preclinical stage of PD, a specific proteasome inhibitor lactacystin (LC) was used. It was injected bilaterally into the SNpc. Immunoblotting methods and confocal microscopy were applied. The LC model of PD was characterized by a pathologic accumulation of total water-soluble and Ser129-phosphorylated forms of α-synuclein, as well as by formation of insoluble α-synuclein aggregates in the DA-neurons of SNpc. TGN-020 caused a significant aggravation of α-synuclein pathology in the LC model of PD. It was manifested by a marked increase in the level of water-soluble and modified forms of α-synuclein and by the 1.9-fold rise in the amount of α-synuclein aggregates in SN. We suppose that the disfunction of AQP4 which is involved in glymphatic system functioning, can be one of the mechanisms leading to the neurodegeneration and accumulation of amyloidogenic proteins in brain parenchyma during PD. The water channel AQP4 might be a target for the development of new therapeutic approaches aimed at attenuation of the cytotoxicity, accumulation and distribution of α-synuclein during the development of PD-like pathology.

Sobre autores

K. Lapshina

Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences

Autor responsável pela correspondência
Email: ksenia.lapshina@gmail.com
Russia, St. Petersburg

M. Khanina

Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences

Email: ksenia.lapshina@gmail.com
Russia, St. Petersburg

M. Kaismanova

Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences

Email: ksenia.lapshina@gmail.com
Russia, St. Petersburg

I. Ekimova

Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences

Email: ksenia.lapshina@gmail.com
Russia, St. Petersburg

Bibliografia

  1. Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, Wang Z (2021) Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019. Front Public Health 9: 776847. https://doi.org/10.3389/fpubh.2021.776847
  2. Montemurro N, Aliaga N, Graff P, Escribano A, Lizana J (2022) New targets and new technologies in the treatment of Parkinson’s disease: A narrative review. Int J Environ Res Public Health 19(14): 8799. https://doi.org/10.3390/ijerph19148799
  3. Raza C, Anjum R, Shakeel NUA (2019) Parkinson’s disease: Mechanisms, translational models and management strategies. Life Sci 226: 77–90. https://doi.org/10.1016/j.lfs.2019.03.057
  4. Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V (2023) Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 14(3): 176. https://doi.org/10.1038/s41419-023-05672-9
  5. Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DM, Hasegawa M (2013) Prion-like spreading of pathological α-synuclein in brain. Brain 136(Pt 4): 1128–1138. https://doi.org/10.1093/brain/awt037
  6. Sorrentino ZA, Giasson BI, Chakrabarty P (2019) α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. Acta Neuropathol 138(1): 1–21. https://doi.org/10.1007/s00401-019-01977-2
  7. Song N, Chen L, Xie J (2021) Alpha-synuclein handling by microglia: Activating, combating, and worsening. Neurosci Bull 7(6): 751–753. https://doi.org/10.1007/s12264-021-00651-6
  8. Frankowska N, Lisowska K, Witkowski JM (2022) Proteolysis dysfunction in the process of aging and age-related diseases. Front Aging 3: 927630. https://doi.org/10.3389/fragi.2022.927630
  9. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, Nagelhus EA, Nedergaard M (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 4(147): 147ra111. https://doi.org/10.1126/scitranslmed.3003748
  10. Nedergaard M (2013) Neuroscience. Garbage truck of the brain. Science 340(6140): 1529–1530. https://doi.org/10.1126/science.1240514
  11. Semyachkina-Glushkovskaya OV, Postnov DE, Khorovodov AP, Navolokin NA, Kurthz JHG (2023) Lymphatic drainage system of the brain: a New player in neuroscience. J Evol Biochem Phys 59: 1–19. https://doi.org/10.1134/S0022093023010015
  12. Ding Z, Fan X, Zhang Y, Yao M, Wang G, Dong Y, Liu J, Song W (2023) The glymphatic system: a new perspective on brain diseases. Front Aging Neurosci 15: 1179988. https://doi.org/10.3389/fnagi.2023.1179988
  13. Hubbard JA, Szu JI, Binder DK (2018) The role of aquaporin-4 in synaptic plasticity, memory and disease. Brain Res Bull 136: 118–129. https://doi.org/10.1016/j.brainresbull.2017.02.011
  14. Harrison IF, Ismail O, Machhada A, Colgan N, Ohene Y, Nahavandi P, Ahmed Z, Fisher A, Meftah S, Murray TK, Ottersen OP, Nagelhus EA, O’Neill MJ, Wells JA, Lythgoe MF (2020) Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model. Brain 143(8): 2576–2593. https://doi.org/10.1016/j.expneurol.2018.04.012
  15. Rosu GC, Catalin B, Balseanu TA, Laurentiu M, Claudiu M, Kumar-Singh S, Daniel P (2020) Inhibition of aquaporin 4 decreases amyloid Aβ40 drainage around cerebral vessels. Mol Neurobiol 57(11): 4720–4734. https://doi.org/10.1007/s12035-020-02044-8
  16. Hoshi A, Tsunoda A, Tada M, Nishizawa M, Ugawa Y, Kakita A (2017) Expression of aquaporin 1 and aquaporin 4 in the temporal neocortex of patients with Parkinson’s Disease. Brain Pathol 27(2): 160–168. https://doi.org/10.1111/bpa.12369
  17. Fang Y, Dai S, Jin C, Si X, Gu L, Song Z, Gao T, Chen Y, Yan Y, Yin X, Pu J, Zhang B (2022) Aquaporin-4 polymorphisms are associated with cognitive performance in Parkinson’s disease. Front Aging Neurosci 13: 740491. https://doi.org/10.3389/fnagi.2021.740491
  18. Sun X, Tian Q, Yang Z, Liu Y, Li C, Hou B, Xie A (2023) Association of AQP4 single nucleotide polymorphisms (rs335929 and rs2075575) with Parkinson’s disease: A case-control study. Neurosci Lett 797: 137062. https://doi.org/10.1016/j.neulet.2023.137062
  19. Cui H, Wang W, Zheng X, Xia D, Liu H, Qin C, Tian H, Teng J (2021) Decreased AQP4 expression aggravates ɑ-synuclein pathology in Parkinson’s disease mice, possibly via impaired glymphatic clearance. J Mol Neurosci 71: 1–14. https://doi.org/10.1007/s12031-021-01836-4
  20. Zhang Y, Zhang C, He XZ, Li ZH, Meng JC, Mao RT, Li X, Xue R, Gui Q, Zhang GX, Wang LH (2023) Interaction between the glymphatic system and α-synuclein in Parkinson’s disease. Mol Neurobiol 60(4): 2209–2222. https://doi.org/10.1007/s12035-023-03212-2
  21. Ekimova IV, Belan DV, Lapshina KV, Pastukhov YuF (2023) The use of the proteasome inhibitor lactacystin for modeling Parkinson’s disease: Early neurophysiological biomarkers and candidates for intranigral and extranigral neuroprotection. In: Handbook of Animal Models in Neurological Disorders. (Eds) Martin CR, Patel VB, Preedy VR. Acad Press, Elsevier. 507–523. https://doi.org/10.1016/B978-0-323-89833-1.00008-2
  22. Ekimova IV, Plaksina DV, Pastukhov YF, Lapshina KV, Lazarev VF, Mikhaylova ER, Polonik SG, Pani B, Margulis BA, Guzhova IV, Nudler E (2018) New HSF1 inducer as a therapeutic agent in a rodent model of Parkinson’s disease. Exp Neurol 306: 199–208. https://doi.org/10.1016/j.expneurol.2018.04.012
  23. McNaught KS, Perl DP, Brownell AL, Olanow CW (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann Neurol 56(1): 149–162. https://doi.org/10.1002/ana.20186
  24. Vernon AC, Johansson SM, Modo MM (2010) Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson’s disease. BMC Neurosci 11: 1. https://doi.org/10.1186/1471-2202-11-1
  25. Savolainen MH, Albert K, Airavaara M, Myöhänen TT (2017) Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson’s disease in young and adult mouse. Exp Brain Res 235(7): 2189–2202. https://doi.org/10.1007/s00221-017-4962-z
  26. Lapshina KV, Abramova YY, Guzeev MA, Ekimova IV (2022) TGN-020, an inhibitor of the water channel aquaporin-4, accelerates nigrostriatal neurodegeneration in the rat model of Parkinson’s disease. J Evol Biochem Phys (58): 2035–2047. https://doi.org/10.1134/S0022093022060308
  27. Nakamura Y, Suzuki Y, Tsujita M, Huber VJ, Yamada K, Nakada T (2011) Development of a novel ligand, [C]TGN-020, for aquaporin 4 positron emission tomography imaging. ACS Chem Neurosci 2(10): 568–571. https://doi.org/10.1021/cn2000525
  28. Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates. 6th Ed. San Diego. Acad Press.
  29. Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T (2011) Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson’s disease. J Neurosci 31(46): 16884–16894. https://doi.org/10.1523/JNEUROSCI.3967-11.2011
  30. Kawahata I, Finkelstein DI, Fukunaga K (2022) Pathogenic impact of α-synuclein phosphorylation and its kinases in α-synucleinopathies. Int J Mol Sci 23(11): 6216. https://doi.org/10.3390/ijms23116216
  31. Si X, Dai S, Fang Y, Tang J, Wang Z, Li Y, Song Z, Chen Y, Liu Y, Zhao G, Zhang B, Pu J (2023) Matrix metalloproteinase-9 inhibition prevents aquaporin-4 depolarization-mediated glymphatic dysfunction in Parkinson’s disease. J Adv Res 20: S2090–S1232. https://doi.org/10.1016/j.jare.2023.03.004
  32. Vandebroek A, Yasui M (2020) Regulation of AQP4 in the Central Nervous System. Int J Mol Sci 21(5): 1603. https://doi.org/10.3390/ijms21051603
  33. Zhang Y, Tan F, Xu P, Qu S (2016) Recent advance in the relationship between excitatory amino acid transporters and Parkinson’s disease. Neural Plast 2016: 8941327. https://doi.org/10.1155/2016/8941327
  34. Liu L, Lu Y, Kong H, Li L, Marshall C, Xiao M, Ding J, Gao J, Hu G (2012) Aquaporin-4 deficiency exacerbates brain oxidative damage and memory deficits induced by long-term ovarian hormone deprivation and D-galactose injection. Int J Neuropsychopharmacol 15(1): 55–68. https://doi.org/10.1017/S1461145711000022
  35. Won SJ, Fong R, Butler N, Sanchez J, Zhang Y, Wong C, Tambou Nzoutchoum O, Huynh A, Pan J, Swanson RA (2022) Neuronal oxidative stress promotes α-synuclein aggregation in vivo. Antioxidants (Basel) 11(12): 2466. https://doi.org/10.3390/antiox11122466
  36. Song N, Chen L, Xie J (2021) Alpha-synuclein handling by microglia: activating, combating, and worsening. Neurosci Bull 37(6): 751–753. https://doi.org/10.1007/s12264-021-00651-6

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar
2.

Baixar (390KB)
Metadados
3.

Baixar (1MB)
Metadados

Declaração de direitos autorais © К.В. Лапшина, М.В. Ханина, М.П. Кайсманова, И.В. Екимова, 2023

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies